Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies.

Abstract

The presence of cutaneous allodynia may predict response to triptans. Identical randomized double-blind studies were conducted comparing the efficacy of rizatriptan 10 mg or placebo administered within 1 h of headache onset, while pain was mild. The primary endpoint was freedom from pain at 2 h. Presence of symptoms suggesting cutaneous sensitivity (SCS) at baseline and at 2 h post-treatment was recorded. Before treatment, 29% of rizatriptan patients and 22% of placebo patients reported SCS. At 2 h, the percentage of patients with SCS was significantly decreased with rizatriptan. The presence of SCS pre-treatment was not predictive of response to rizatriptan. Most patients with SCS at 2 h were non-responders. Early treatment with rizatriptan significantly reduced the percentage of patients with SCS at 2 h. The presence of SCS at baseline did not predict pain-free response, but presence of SCS at 2 h correlated with lack of a 2-h pain-free response.

• Authors: R Cady, V Martin, A Mauskop, A Rodgers, C M Hustad, K E Ramsey, F Skobieranda
• Journal: Cephalalgia : an international journal of headache (Cephalalgia) Vol. 27 Issue 9 Pg. 1055-60 (Sep 2007) ISSN: 0333-1024 [Print] England
• PMID: 17681023 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Serotonin Receptor Agonists
• Triazoles
• Tryptamines
• rizatriptan

Topics

• Adult
• Comorbidity
• Double-Blind Method
• Female
• Headache (drug therapy, epidemiology)
• Humans
• Hyperalgesia (drug therapy, epidemiology)
• Male
• Migraine Disorders (drug therapy, epidemiology)
• Placebo Effect
• Prevalence
• Randomized Controlled Trials as Topic
• Risk Assessment (methods)
• Risk Factors
• Serotonin Receptor Agonists (therapeutic use)
• Touch
• Treatment Outcome
• Triazoles (therapeutic use)
• Tryptamines (therapeutic use)
• United States (epidemiology)